Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: Results from a 128-patient monocenter registry

Chest

Volumn 120, Issue 1, 2001, Pages 120-125

  Hamel, Emmanuel ^a   Pacouret, Gérard ^a   Vincentelli, Dominique ^a   Forissier, Jean François ^a   Peycher, Patrick ^a   Pottier, Jean Marie ^a   Charbonnier, Bernard ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

Heparin; Low molecular weight heparin; Massive pulmonary embolism; Right ventricular dysfunction; Thrombolysis

Indexed keywords

HEPARIN;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART RIGHT VENTRICLE; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HEPARINIZATION; HUMAN; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; VASODILATATION;

EID: 0034880846     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.1.120     Document Type: Article

References (29)

1. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism
2. The Urokinase Pulmonary Embolism Trial: A national cooperative study
3. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism
4. Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: Plasminogen Activator Italian Multicenter Study 2
5. Antithrombotic therapy for venous thromboembolic disease: Fifth ACCP Consensus Conference of Antithrombotic Therapy
6. Mortality in patients treated for pulmonary embolism
7. Alteplase versus heparin in acute pulmonary embolism: Randomized trial assessing right-ventricular function and pulmonary perfusion
8. Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry
9. Association between thrombolytic treatment and the prognosis of hemo-dynamically stable patients with major pulmonary embolism: Results of a multicenter registry
10. Value of ventilation/perfusion scans versus perfusion scans alone in acute pulmonary embolism
11. Echocardiographic findings in patients with proved pulmonary embolism
12. Echocardiographic pattern of acute cor pulmonale
13. Echocardiographic evaluation of pulmonary embolism and its response to therapeutic interventions
14. The role of ultrasonography in the diagnosis of moderate to severe pulmonary embolism
15. Doppler echocardiographic evaluation of the efficacy of fibrinolytic treatment of pulmonary embolism
16. Echocar-diography Doppler in pulmonary embolism: Right ventricular dysfunction as a predictor of mortality rate
17. Thrombolytic therapy for pulmonary embolism: Frequency of intracranial hemorrhage and associated risk factors
18. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS Equivalence Trial; Comparison Trial of Saruplase and Streptokinase (CO-MASS) Investigators
19. Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: Results of the PASS study
20. Rapid hemodynamic improvement following saruplase in recent massive pulmonary embolism
21. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
22. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism
23. A comparison of low molecular weight heparin with unfractionated heparin for acute pulmonary embolism
24. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
25. Pulmonary embolism: One-year follow-up with echocardiography Doppler and five-year survival analysis
26. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: A comparison with nonelderly patients
27. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy
28. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years